HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02320032

Aripiprazole Lauroxil Safety and Drug Levels in Stable Schizophrenia

About this titleRead the official source — NCT02320032
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 15 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2014
Recruitment status
Completed
Enrollment listed in the registry
140
Sponsor
Alkermes, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02320032
Official title
Show the full official title

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Cerritos · Garden Grove

13 more locations
  • Washington D.C.
  • Lauderhill
  • Leesburg
  • Maitland
  • Oakland Park
  • Tampa
  • Atlanta
  • Chicago
  • Hoffman Estates
  • St Louis
  • Marlton
  • Austin
  • Dallas
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole Lauroxil.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies